Founded in 2022 by Cambridge-trained researchers Ben Woodington and Elise Jenkins, San Francisco–based Coherence Neuro decodes the body’s electrical patterns to understand and correct disease states. Its flagship device, SOMA-1, continually records neural activity and delivers precise stimulation, creating a bi-directional, closed-loop therapy that aims to nudge tumorous tissue back toward healthy function. Each deployed device feeds data into what the company calls the world’s largest disease-focused dataset, allowing the system to learn and improve with every patient. Coherence frames cancer as a system-level error rather than an external invader, seeking to replace aggressive treatments like surgery and chemotherapy with continuous, gentler neuromodulation. The company plans to begin first-in-human trials next year, using its newly secured capital to validate safety and efficacy. To date, it has raised a $10 million seed round to fund these efforts and further develop its data-driven platform.

Total raised

$12M

Funding rounds

2

Latest round

Seed

Latest activity

Nov 2025